Sotrovimab
Educational summary, not a formulary. Dosing is quoted from the Makindo chapters and topics site. The other sections are draft summaries not yet checked line by line against the BNF or SPC. Check dose, indication, interactions and monitoring in the BNF entry for Sotrovimab and local guidelines before prescribing.
Antiviral antibody
Mechanism
SARS-CoV-2 neutralising monoclonal antibody.
Uses
COVID-19 in high-risk patients (variant-dependent).
Dosing
No dose is given in the chapters. See the BNF.
Side effects
Infusion reactions, rash, diarrhoea.
Interactions
Few.
Contraindications and cautions
Hypersensitivity
Monitoring
Infusion reactions
Pregnancy and breastfeeding
Limited data
Renal and hepatic impairment
No adjustment
Overdose and reversal
Supportive
Special advice
Efficacy depends on circulating variant.
More from the textbook: uses, cautions and other points
- Early antivirals for people at high risk of severe disease (within 5 days of symptoms) - nirmatrelvir–ritonavir (major interactions), sotrovimab or remdesivir (NICE).
ID: Viral, fungal and parasitic infections - Sotrovimab (neutralising antibody), remdesivir (IV, hospital use).
ID: How Infection Happens - SARS-CoV-2 (COVID-19) - ACE2 receptor; spectrum from asymptomatic to ARDS, thrombosis, myocarditis, long COVID; antivirals for high-risk outpatients (nirmatrelvir–ritonavir, molnupiravir, sotrovimab per NICE), dexamethasone for patients needing oxygen, IL-6 inhibitors in severe disease; seasonal boosters for older and vulnerable groups.
Microbiology: Virology - structure, replication and important viral infections